Canaccord Genuity restated their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report report published on Wednesday morning. The brokerage currently has a $522.00 price target on the biopharmaceutical company’s stock.

“We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN.”,” the firm’s analyst wrote.

Several other research analysts have also weighed in on the company. Zacks Investment Research lowered Regeneron Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, February 5th. Jefferies Group reiterated a hold rating and set a $421.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, February 2nd. BidaskClub upgraded Regeneron Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, January 26th. JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the stock a neutral rating in a research note on Wednesday, January 24th. Finally, Citigroup reiterated a neutral rating and set a $388.00 price target (up previously from $380.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, January 9th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of Hold and an average price target of $463.19.

Regeneron Pharmaceuticals (REGN) opened at $336.38 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.14 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a 52-week low of $314.99 and a 52-week high of $543.55. The firm has a market capitalization of $37,680.00, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.22 and a beta of 1.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping the consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period in the prior year, the firm posted $3.04 EPS. The business’s revenue was up 28.9% compared to the same quarter last year. sell-side analysts anticipate that Regeneron Pharmaceuticals will post 14.13 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the stock. Harding Loevner LP boosted its stake in Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares during the period. Polen Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock valued at $522,413,000 after purchasing an additional 15,931 shares during the period. American Century Companies Inc. boosted its stake in Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock valued at $410,257,000 after purchasing an additional 20,218 shares during the period. Orbimed Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 22.7% during the 3rd quarter. Orbimed Advisors LLC now owns 572,770 shares of the biopharmaceutical company’s stock valued at $256,097,000 after purchasing an additional 106,000 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in Regeneron Pharmaceuticals by 93.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 553,501 shares of the biopharmaceutical company’s stock valued at $208,094,000 after purchasing an additional 267,442 shares during the period. Hedge funds and other institutional investors own 65.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://theolympiareport.com/2018/02/11/regeneron-pharmaceuticals-regn-stock-rating-reaffirmed-by-canaccord-genuity.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.